GEN3018

GEN3018 is an investigational bispecific antibody developed by Genmab using its proprietary DuoBody technology platform. It is designed to simultaneously target CD123 (the alpha chain of the interleukin-3 receptor) and CD3 on T cells. CD123 is highly expressed on the surface of leukemic blasts and leukemic stem cells in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), while being minimally expressed on normal hematopoietic stem cells. By binding both targets, GEN3018 facilitates the recruitment and activation of cytotoxic T cells directly to CD123-expressing malignant cells, inducing targeted cell lysis. The drug is currently being evaluated in a first-in-human Phase 1 clinical trial for patients with relapsed or refractory AML and higher-risk MDS.

Other names

DuoBody-CD3xCD123DuoBody-CD-3xCD123DuoBody-CD 3xCD123